The times when a company is dominating headlines (for all the wrong reasons) are the best time to buy. Take Medibank Private (ASX: MPL), for example, which you may remember, was embroiled in a data breach in October 2022. On the news, the stock's share price plummeted more than 20%. And while it still hasn't retraced its steps to its prior glory, astute investors who picked up the private health insurance provider on the cheap would have since enjoyed a return of around 22%. Today, there are two businesses on the ASX that are similarly making headlines: ResMed (ASX: RMD) and Qantas (ASX: QAN). And while one of these businesses is likely to continue to face headwinds going forward, the other could just be the "most outstanding buy idea on the ASX" today. That's according to Airlie Funds Management's Emma Fisher, who believes if a company's balance sheet is intact, times of "maximum pain" are usually an investor's best indicator that a business is a buy. In this episode, Livewire's Ally Selby learns where Emma is seeing the most value on the ASX today, why the data proves it pays to be bullish on the stock market over the long term, what separates the good investors from the great ones, as well as a deep dive on why the team is still buying CSL (ASX: CSL) despite downgrading the stock. Plus, she also shares why she believes the market is focusing far too much on the macro, as well as the stock she would back if the market were to close for the next five years. Note: This episode was recorded on Wednesday 27 September 2023. Timecodes: 0:00 - Intro 1:26 - How Emma Fisher thinks about investing 4:06 - Why we need a reality check 6:45 - What keeps Emma Fisher inspired 9:42 - The biggest changes in the Airlie Australian Share Fund portfolio and key lessons from the past two years in markets 13:11 - Portfolio holdings that have been more resilient than expected: James Hardie (ASX: JHX) 14:20 - Why being bearish may sound smart, but being bullish makes money 17:01 - Times of maximum fear are the best times to make money: The Medibank (ASX: MPL) example 19:57 - Emma's analysis of Qantas (ASX: QAN) and ResMed (ASX: RMD) 27:07 - What separates the good investors from the exceptional ones - and it's not a high IQ 29:37 - The biases Emma has learnt to manage - and how you can too 32:03 - Where Emma is seeing the most value today 37:45 - Analysis of CSL and the Vifor acquisition 42:46 - One thing investors are getting wrong about markets 43:48 - A story of a big loss from Emma's career and what she learnt from it 46:12 - Why cashflow is paramount 46:35 - One stock that Emma would hold if the markets were to close for five years: ResMed (ASX: RMD)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related